After dealing with a deployment issue with glucose monitors earlier this year, interim CEO Jake Leach said improving customer ...

Q3 2025 Earnings Call Transcript October 30, 2025 DexCom, Inc. beats earnings expectations. Reported EPS is $0.61, ...

Medical device company DexCom (NASDAQ:DXCM) reported Q3 CY2025 results beating Wall Street’s revenue expectations, with sales ...

DexCom Inc (DXCM) reports a robust 22% increase in worldwide revenue, driven by expanded CGM access and strategic market ...

DexCom, Inc. DXCM reported third-quarter 2025 adjusted earnings per share (EPS) of 61 cents, which beat the Zacks Consensus ...

Get key insights from DexCom’s Q3 2025 earnings: robust revenue growth, new product launches, updated guidance, and future opportunities.

Thank you, operator, and welcome to DexCom's Third Quarter 2025 Earnings Call. Our agenda begins with Jake Leach, DexCom's President and Interim CEO, who will summarize our recent highlights and ...

DexCom posts Q3 revenue of $1.21 billion, beating estimates and raising 2025 guidance as analysts expect strong sales and margin improvement ahead.

DexCom Inc. (DXCM) reported its third-quarter earnings for 2025, surpassing analysts’ expectations with an EPS of $0.61 compared to a forecasted $0.57, marking a 7.02% earnings surprise. Revenue also ...

Dexcom (($DXCM)) has held its Q3 earnings call. Read on for the main highlights of the call. DexCom’s recent earnings call conveyed a generally ...

Dexcom Inc. executives may have thought a $30 million beat ... following issues with its G7 sensor, which management said have been largely resolved.